ALS Strategy & Access Liaison

Otsuka Pharmaceutical Co., Ltd; United States; On-site; USD 158,000 - 252,000; Full time

Benefits offered by this job

Comprehensive benefits

401(k) match

Paid holidays and leave

Job summary

Otsuka Pharmaceutical Co., Ltd. is seeking a Strategic Account Liaison to support the launch and growth of its Rare Neurology Franchise, focusing on ALS. You will translate complex clinical data, screening pathways, and access information to ALS Centers of Excellence, healthcare providers, and key stakeholders.

The role emphasizes strategic account management, market access collaboration, and proactive engagement to advance patient care and optimize therapy uptake in the U.S. market.

Qualifications

• Bachelor's degree required.
• 8+ years in Biotech/Pharma commercial roles with launches, IDN navigation, and KOL engagement.
• Rare or ultra-rare disease experience preferred.

Responsibilities

• Communicate complex clinical data and treatment pathways to ALS centers, HCPs, and stakeholders.
• Develop and execute regional strategic account plans and pull-through of access programs.
• Navigate hospital purchasing, coding, and reimbursement processes to enable therapy access.
• Collaborate with Market Access, Patient Support, and cross-functional partners to remove barriers to therapy.
• Represent the brand at conferences and scientific meetings to educate on rare neurology.

Skills

Clinical acumen

Customer engagement

KOL engagement

Cross-functional collaboration

Account management

Education

Bachelor's Degree

Job description

Otsuka Pharmaceutical Co., Ltd. is seeking a Strategic Account Liaison to support the launch and growth of its Rare Neurology Franchise, focusing on ALS. You will translate complex clinical data, screening pathways, and access information to ALS Centers of Excellence, healthcare providers, and key stakeholders.

The role emphasizes strategic account management, market access collaboration, and proactive engagement to advance patient care and optimize therapy uptake in the U.S. market.